[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,94,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634527","regular-diet-after-colorectal-surgery-100634527",false,"NCT07540845","Regular Diet After Colorectal Surgery","Impact of Postoperative Regular Diet on Colorectal Outcomes and Patient Quality of Life","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Scheduled to undergo colorectal resection\n\nExclusion Criteria:\n\n* Patients with bowel obstructions\n* Patients below the age of 18","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot study is to assess the safety and feasibility of regular diet after surgical removal of the colon. The study will enroll patients preoperatively, prior to colon surgery, and will follow participants for up to 30 days. The study hypothesizes that simplifying nutritional recommendations is safe and may improve quality of life.",[26,27,28,29],"Colorectal","Diet Habits","Surgery","Post-operative Care",[31,32],"diet after surgery","nutrition counseling","RECRUITING","2026-05-20",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":37},"2026-05-13",{"date":41,"type":20},"2027-01-31",{"name":43,"class":44},"Weill Medical College of Cornell University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100626137","creation-of-compression-anastomosis-using-the-gt-metabolic-magnet-system-100626137","NCT07431723","Creation of Compression Anastomosis Using the GT Metabolic Magnet System","Creation of Compression Anastomosis Using the GT Metabolic Magnet System as Either the Primary or the First Stage of Colorectal Surgery (MagCR Study)","MagCR","Inclusion Criteria:\n\n* Indicated for colorectal surgery requiring anastomosis within the colon or colon and distal small bowel (i.e., colocolic, colorectal, rectalrectal, ileocolic, or ileorectal) performed side-to-side or endto-end with ileostomy\n* Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.\n\nExclusion Criteria:\n\n* High frailty index, with a score of ≥ 3 on the five-item modified frailty index (mFI-5).\n* Severe Sarcopenia as determined by the investigator.\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the procedure, including scarring and abnormal anatomy at the target anastomosis sites.\n* Any anomaly precluding orogastric access by colonoscope and catheters, and manipulation techniques.\n* Any anomaly preventing \u002F contraindicating colonoscopic or laparoscopic access and procedures.\n* Implantable pacemaker or defibrillator (and\u002For other devices that may be impacted by or interfere with the Magnet System).\n* Psychiatric disorder, except well-controlled depression with medication for \\> 6 months.\n* Pregnant, lactating, or planning pregnancy during the clinical investigation.\n* Any comorbidity or current status of participant's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the participant medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.\n* Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment site.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months post-procedure.\n* Any surgical or interventional procedure (including planned and\u002For scheduled) within the period of 30 days prior to and 30 days following the study procedure.\n* Any stroke\u002FTransient Ischemic Attack (TIA) ≤ 6 months prior to consent.\n* Requires chronic anticoagulation therapy (except aspirin).\n* Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.\n* Current tobacco \u002F nicotine product usage or recent product cessation ≤ 3 months prior to informed consent.\n* Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.\n* Participants with comorbidities that are likely to result in a life expectancy ≤ 12 months.\n* Currently participating in an investigational drug or another device study that has not reached its primary endpoint\n* Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.","75 Years",{"count":56,"type":20},50,[23],"Evaluate the performance and safety of the Magnet System to create anastomoses throughout the large bowel and between the large and distal small bowel.",[60,26],"Anastomosis, Functional",[62,63],"Magnet System","GT Metabolic Solutions, Inc.","2026-05-18",{"date":66,"type":37},"2026-05-19",{"date":68,"type":37},"2026-02-16",{"date":70,"type":20},"2028-02",{"name":63,"class":72},"INDUSTRY",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100512083","a-prospective-feasibility-study-using-ctdna-to-tailor-neoadjuvant-chemotherapy-for-patients-with-colorectal-or-appendiceal-adenocarcinoma-100512083","NCT05947838","A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma","Inclusion Criteria:\n\n* Histologically\u002Fcytologically confirmed diagnosis of moderate or poorly differentiated appendiceal or colorectal adenocarcinoma of any grade with Initial resectable disease.\n* Have metastatic peritoneal disease that is visible on imaging or at the time of laparoscopy.\n* Age ≥18 years. Because no adverse event data are currently available on the use of ctDNA in chemotherapy decision making in patients \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status ≤1 (Karnofsky ≥70%,).\n* Patients must have adequate organ and marrow function as defined below:\n\nabsolute neutrophil count ≥1,000\u002FmcL platelets ≥100,000\u002FmcL total bilirubin 1.5x ≤ institutional upper limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN Creatinine clearance ≥30 mL\u002Fmin\n\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are not eligible.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* Estimated life-expectancy of \\> 4 months.\n* The effects of standard chemotherapeutic agents used in this trial (5-fluouracil, oxaliplatin, leucovorin, and irinotecan) on the developing human fetus are detrimental. For this reason and because these agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of their chemotherapy administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n* English and Non-English-speaking.\n\nExclusion Criteria:\n\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients with brain or other visceral (i.e. liver and\u002For lung) metastases at the discretion of the investigator.\n* Patients with uncontrolled intercurrent illness (Indicate clearly what type or extent)\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because chemotherapeutic agents used carry the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued if the mother is treated with chemotherapy. These potential risks may also apply to other agents used in this study.\n* If participant received major surgery within last 4 weeks, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n* Serious adverse chemotherapy related adverse events (grade 3 or 4) that were symptomatic and required prolong chemotherapy break (\\>6weeks).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the study subject's best interest to participate, in the opinion of the treating investigator.",{"count":81,"type":20},48,[23],"To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment before surgery. ctDNA testing measures the amount of tumor DNA (genetic information) in the blood.",[85,26],"Appendiceal Adenocarcinoma","2026-05-14",{"date":64,"type":37},{"date":89,"type":37},"2023-12-04",{"date":91,"type":20},"2027-04-30",{"name":93,"class":44},"M.D. Anderson Cancer Center",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":5},"100583714","a-study-to-understand-the-utility-of-the-force-feedback-instruments-in-robotic-procedures-using-da-vinci-5-robot-100583714","NCT06879912","A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot","A Prospective, Post-Market Study to Evaluate the Clinical Utility of the Force Feedback Instruments in RAS Procedures Using the da Vinci 5 Surgical System","Pre-Operative Inclusion Criteria:\n\n1. Age 22 years or older\n2. ASA ≤ 3\n3. The clinical decision has been made to perform multi-port robotic assisted surgery with da Vinci 5 with Force Feedback instruments for the study specified procedure as primary procedure prior to enrollment in the study\n4. Subject or a legally authorized representative is able to provide written informed consent using the study informed consent form prior to the study\n5. Subject is willing and able to comply with the study protocol requirements including follow up schedule\n\nPre-operative Exclusion Criteria:\n\n* Subject receiving an emergent procedure\n* Subject planned to undergo major concomitant surgery for the treatment of a different medical condition than was originally planned\n* Subject with previous ipsilateral surgery (open, endoscopic or robotic) with the same surgical indication\n* Subject with past or ongoing medical conditions (for example: inflammatory bowel disease) which, in the judgment of the Investigator, puts them at high risk for surgery and not appropriate for the study\n* Subject is pregnant or suspected to be pregnant or breastfeeding\n* Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data\n* Subject is currently participating in or has participated in a study of an investigational agent or a significant risk investigational device study within the past 6 months\n* Subject belongs to a vulnerable population.\n* Subject is contraindicated for anesthesia or surgery.\n* Subject has had previous neoadjuvant therapy, previous chemotherapy, immunotherapy, and\u002For radiation therapy for the treatment of the cancer to be resected within the past 6 months\n\nIntra-operative Exclusion Criteria\n\n* Subject with hemodynamic or respiratory instability, which precludes the Investigator from performing the RAS.\n* Subject in whom inadequate visualization makes a minimally invasive approach not feasible, as determined from the investigator assessment prior to docking the robot.\n* Subject with adhesions, scarring and disease status in the body which in the opinion of the investigator limits the ability to perform the minimally invasive procedure.","22 Years",{"count":103,"type":20},200,"OBSERVATIONAL","The goal of this observational study is to understand the utility of force feedback instruments in surgeries that are done using the da Vinci 5 robot.",[107,108,26,109,110,111],"Hernia, Inguinal","Hernia, Ventral","Thoracic","Gynecologic","Partial Nephrectomy","2026-02-23",{"date":114,"type":37},"2026-02-25",{"date":116,"type":37},"2025-05-22",{"date":118,"type":20},"2026-08",{"name":120,"class":72},"Intuitive Surgical",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":45},"100606527","same-day-colectomy-is-it-safe-for-patients-100606527","NCT07176715","Same-Day Colectomy: is it Safe for Patients?","Inclusion Criteria:\n\n* Ages 18-70\n* Undergoing robotic-assisted right colectomy, sigmoidectomy, or low anterior resection.\n* Able to perform greater than 4 metabolic equivalents (METS) without shortness of breath\n* Must have a designated adult who can care for them at home postoperatively until their in-person clinic visit\n* Access to a cell phone or computer and running water.\n* Successfully completed pre-operative and post-operative education\n* Medical criteria:\n* Well controlled hypertension with systolic blood pressure \\\u003C 140 controlled by less than two medications which they are compliant with\n* Well controlled diabetes on oral agents only with blood glucose level \\\u003C 180 on daily checks\n* Anti-platelet agents including aspirin, clopidogrel, prasugrel, ticagrelor or ticlopidine will be stopped 7 days preoperatively and restarted on postoperative day 1. See exclusion criteria 7 for specific exclusion criteria regarding antiplatelet agents.\n\nExclusion Criteria:\n\n* Medical criteria:\n* Neurocognitive deficits not allowing for adequate preoperative education\n* Congestive heart failure with EF \\\u003C 45%\n* Symptomatic aortic stenosis causing heart failure, syncope, dyspnea or angina\n* Pulmonary fibrosis or pulmonary hypertension\n* COPD or home oxygen use \\> 2L\n* Chronic kidney disease of any stage.\n* Lack of a caregiver at home or functionally bed-bound\n* Ultralow pelvic resection\n* Need for ostomy creation intraoperatively\n* Operative time greater than 5 hours as this likely indicates a complex case and dissection necessitating closer monitoring in the hospital\n* Conversion to open procedure intraoperatively\n* Patients receiving antiplatelet agents such as clopidogrel, prasugrel, ticagrelor or ticlopidine within one year of coronary or carotid stent implantation, TAVR or LAAO placement.\n* Patients on therapeutic anticoagulation medications such as warfarin, Eliquis, Xarelto, Enoxaparin\n* Current tobacco use\n* Patients who were unable to complete preoperative education, do not feel comfortable with care at home, or do not have an available caregiver for the first 7 postoperative days\n* Any surgical history that would preclude safe abdominal entry for robotic surgery","70 Years",{"count":129,"type":20},150,[23],"This is a prospective cohort study of outcomes of patients undergoing outpatient colorectal surgery at a single institution to study outpatient colectomy as a viable treatment option for a select group of patients requiring colon and rectal surgery.",[26,133,134],"Colectomy","Colectomy Left\u002FRight\u002FTotal Under Laparotomy",[136,137],"Same Day Colectomy","outpatient Colectomy","2025-09-09",{"date":140,"type":37},"2025-09-16",{"date":142,"type":20},"2025-09-15",{"date":144,"type":20},"2030-09-01",{"name":146,"class":44},"University of Arizona"]